Survival Improvements in Advanced Hepatocellular Carcinoma with Sequential Therapy by Era
出版年份 2023 全文链接
标题
Survival Improvements in Advanced Hepatocellular Carcinoma with Sequential Therapy by Era
作者
关键词
-
出版物
Cancers
Volume 15, Issue 21, Pages 5298
出版商
MDPI AG
发表日期
2023-11-06
DOI
10.3390/cancers15215298
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Clinical Practice Guidelines for Hepatocellular Carcinoma: The Japan Society of Hepatology 2021 version (5th JSH‐HCC Guidelines)
- (2023) Kiyoshi Hasegawa et al. HEPATOLOGY RESEARCH
- Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA.
- (2022) Ghassan K. Abou-Alfa et al. JOURNAL OF CLINICAL ONCOLOGY
- New treatment paradigm with systemic therapy in intermediate-stage hepatocellular carcinoma
- (2022) Masatoshi Kudo International Journal of Clinical Oncology
- Current status of primary liver cancer and decompensated cirrhosis in Japan: launch of a nationwide registry for advanced liver diseases (REAL)
- (2022) Kazuya Okushin et al. JOURNAL OF GASTROENTEROLOGY
- Does first‐line treatment have prognostic impact for unresectable HCC ?—Atezolizumab plus bevacizumab versus lenvatinib
- (2022) Atsushi Hiraoka et al. Cancer Medicine
- Global burden of primary liver cancer in 2020 and predictions to 2040
- (2022) Harriet Rumgay et al. JOURNAL OF HEPATOLOGY
- Hepatocellular carcinoma
- (2021) Josep M. Llovet et al. Nature Reviews Disease Primers
- A Survey of Survival Outcomes for Targeted Cancer Drugs Approved by the US Food and Drug Administration
- (2021) Qian He et al. Therapeutic Innovation & Regulatory Science
- Disease Burden, Risk Factors, and Recent Trends of Liver Cancer: A Global Country-Level Analysis
- (2021) Junjie Huang et al. Liver Cancer
- Management of Hepatocellular Carcinoma in Japan: JSH Consensus Statements and Recommendations 2021 Update
- (2021) Masatoshi Kudo et al. Liver Cancer
- Report of the 22nd Nationwide Follow‐Up Survey of Primary Liver Cancer in Japan (2012–2013)
- (2021) Masatoshi Kudo et al. HEPATOLOGY RESEARCH
- Early experience of atezolizumab plus bevacizumab therapy in Japanese patients with unresectable hepatocellular carcinoma in real-world practice
- (2021) Yuka Hayakawa et al. INVESTIGATIONAL NEW DRUGS
- Evolution of Survival Impact of Molecular Target Agents in Patients with Advanced Hepatocellular Carcinoma
- (2021) Kazufumi Kobayashi et al. Liver Cancer
- Global incidence trends in primary liver cancer by age at diagnosis, sex, region, and etiology, 1990‐2017
- (2020) Zhenqiu Liu et al. CANCER
- Trial Design and Endpoints in hepatocellular carcinoma: AASLD Consensus Conference
- (2020) Josep M. Llovet et al. HEPATOLOGY
- Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
- (2020) Richard S. Finn et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Changing Paradigm for the Treatment of Intermediate-Stage Hepatocellular Carcinoma: Asia-Pacific Primary Liver Cancer Expert Consensus Statements
- (2020) Masatoshi Kudo et al. Liver Cancer
- Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2019) Andrew X Zhu et al. LANCET ONCOLOGY
- Temporal trends in disease presentation and survival of patients with hepatocellular carcinoma: A real-world experience from 1998 to 2015
- (2018) Nathan G. Kim et al. CANCER
- Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial
- (2018) Masatoshi Kudo et al. LANCET
- Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma
- (2018) Ghassan K. Abou-Alfa et al. NEW ENGLAND JOURNAL OF MEDICINE
- Outcomes of patients (pts) with hepatocellular carcinoma (HCC) treated with transarterial chemoembolization (TACE): Global OPTIMIS final analysis.
- (2018) Markus Peck-Radosavljevic et al. JOURNAL OF CLINICAL ONCOLOGY
- A nationwide survey on non-B, non-C hepatocellular carcinoma in Japan: 2011–2015 update
- (2018) Ryosuke Tateishi et al. JOURNAL OF GASTROENTEROLOGY
- Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2017) Jordi Bruix et al. LANCET
- Hepatocellular carcinoma
- (2016) Josep M. Llovet et al. Nature Reviews Disease Primers
- Management of Hepatocellular Carcinoma in Japan: Consensus-Based Clinical Practice Guidelines Proposed by the Japan Society of Hepatology (JSH) 2010 Updated Version
- (2011) Masatoshi Kudo et al. DIGESTIVE DISEASES
- Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
- (2008) Ann-Lii Cheng et al. LANCET ONCOLOGY
- Sorafenib in Advanced Hepatocellular Carcinoma
- (2008) Josep M. Llovet et al. NEW ENGLAND JOURNAL OF MEDICINE
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started